GLP-1 Weight Loss Drugs May Worsen Muscle Loss in Older Adults — Should We Worry? | Research

The takeaway

Older adults on GLP-1 drugs risk sarcopenic obesity from muscle loss during treatment and fat regain after stopping, especially with weight cycling.

2/3 discontinue
Up to two-thirds of GLP-1 users stop within a year, risking weight cycling and sarcopenic obesity

What the researchers found

GLP-1 drug-induced weight loss plus high discontinuation rates create a risk for sarcopenic obesity in older adults through muscle loss and weight cycling.

Why it matters

Sarcopenic obesity increases disability, falls, and mortality in older adults — if GLP-1 drugs contribute to it, treatment strategies must be adapted.

The numbers in context

15-25% weight loss over 12-24 months; up to 2/3 discontinue within 1 year; ~50% reinitiate; sarcopenic obesity prevalence 10-20% in older adults.

How the study worked

Expert commentary/narrative review analyzing GLP-1 weight loss, adherence data, and sarcopenic obesity risk.

Who was studied

Older adults using GLP-1 RAs for obesity

What this study cannot tell us

Commentary based on extrapolation from existing data — direct evidence of GLP-1-induced sarcopenic obesity in older adults is limited.

How to read the evidence

Expert commentary — raises important concerns supported by indirect evidence but lacking direct longitudinal data.

When this study was published

Published in 2025, addressing a critical gap in GLP-1 safety considerations for geriatric populations.

The bigger picture

The GLP-1 revolution must account for age-specific risks — what works for younger patients may create new problems in the elderly.

Questions still open

Should older adults on GLP-1 drugs receive mandatory resistance exercise prescriptions?
Can protein supplementation mitigate muscle loss during GLP-1 treatment?

Common questions

Can GLP-1 drugs cause muscle loss?

Weight loss from any method includes some muscle. For older adults, this is concerning because it can lead to sarcopenic obesity — too little muscle combined with excess fat.

What happens if I stop and restart a GLP-1 drug?

Weight cycling (losing and regaining weight) may preferentially regain fat rather than muscle, potentially worsening body composition over time.

Read the original research

Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?

The journal of nutrition, health & aging, 29(10), 100652

View on PubMed ↗Publisher’s paper ↗

Citation

Prokopidis, Konstantinos; Daly, Robin M; Suetta, Charlotte. (2025). Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?. The journal of nutrition, health & aging, 29(10), 100652. https://doi.org/10.1016/j.jnha.2025.100652